Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
10/2001
10/11/2001WO2001074394A1 New combination of a betablocker and a cholesterol-lowering agent
10/11/2001WO2001074379A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
10/11/2001WO2001074299A2 Compositions and methods for inhibition of cancer invasion and angiogenesis
10/11/2001WO2001074180A1 Nutritional supplements for stimulating bone growth
10/11/2001WO2001074173A1 Supplementation of equine feedstuffs
10/11/2001WO2001027119A3 Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines
10/11/2001WO2001025269A3 Human g-protein coupled receptor
10/11/2001WO2001025210A3 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands
10/11/2001WO2001021587A3 Hydroxyfunctional amide 1h-indole derivatives active as spla2 inhibitors
10/11/2001WO2000017176A3 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments
10/11/2001US20010029617 Therapeutic and diagnostic tools for impaired glucose tolerance conditions
10/11/2001US20010029248 Composition for and method of reducing low density lipoprotein cholesterol concentration
10/11/2001US20010028898 Steam boiling, drying, reboiling
10/11/2001US20010028896 Controlled release lipoic acid
10/11/2001DE10017102A1 Verfahren zur Herstellung von festen Kreatin-Dosierungsformen und dadurch erhältliche Dosierungsformen A process for producing solid creatine dosage forms and dosage forms obtainable thereby
10/11/2001DE10015479A1 Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität Solid oral dosage forms with delayed release and high mechanical stability
10/11/2001CA2404896A1 Human ion channel protein and polynucleotides encoding the same
10/11/2001CA2404592A1 Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/11/2001CA2404541A1 G-protein coupled receptors and nucleic acids encoding same
10/11/2001CA2404526A1 Protein amf-1 to amf-10 and nucleic acids encoding the same
10/11/2001CA2404376A1 O-glucosylated benzamide sglt2 inhibitors and method
10/11/2001CA2404373A1 O-aryl glucoside sglt2 inhibitors and method
10/11/2001CA2404350A1 Control of a gene induced by oxidized lipids in human artery wall cells
10/11/2001CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001CA2403160A1 New combination of a betablocker and a cholesterol-lowering agent
10/11/2001CA2402586A1 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
10/11/2001CA2402416A1 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
10/11/2001CA2401948A1 Cd20/ige-receptor like molecules and uses thereof
10/11/2001CA2399399A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
10/11/2001CA2368966A1 New derivatives and analogues of galanthamine
10/10/2001EP1143000A1 Screening method
10/10/2001EP1142900A1 Siastatin b derivatives having glycosidase inhibitory activities and process for producing the same
10/10/2001EP1142890A1 Aminopyrazole derivatives
10/10/2001EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents
10/10/2001EP1142886A1 Percyquinnin, a process for its production and its use as a pharmaceutical
10/10/2001EP1142885A1 Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives
10/10/2001EP1142880A1 Benzimidazole derivatives
10/10/2001EP1142879A1 Imidazole compounds and medicinal use thereof
10/10/2001EP1142870A1 Novel ligands of nuclear receptor
10/10/2001EP1142867A2 Cell adhesion inhibitors
10/10/2001EP1142590A1 Gene therapy for diabetic ischemic disease
10/10/2001EP1142571A1 Method to produce solid creatine dosage forms and dosage forms thus obtained
10/10/2001EP1141728A1 Kidney disease detection and treatment
10/10/2001EP1141395A1 Single nucleotide polymorphism in a pyruvate dehydrogenase kinase isoenzyme 2 (pdk2) in humans
10/10/2001EP1141334A2 Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof
10/10/2001EP1141332A1 Human cyclic nucleotide pdes
10/10/2001EP1141288A2 Lymphocytic membrane proteins
10/10/2001EP1141287A1 Pancreatic polypeptide zsig66
10/10/2001EP1141278A2 Therapeutic phosphodiesterase inhibitors
10/10/2001EP1141274A2 Soluble receptor br43x2 and methods of using them for therapy
10/10/2001EP1141266A2 Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof
10/10/2001EP1141252A2 Human desaturase gene and uses thereof
10/10/2001EP1141240A1 Use of cd40 engagement to alter t cell receptor usage
10/10/2001EP1141020A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/10/2001EP1141017A2 Characterization of the soc/crac calcium channel protein family
10/10/2001EP1141015A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001EP1141014A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001EP1141013A2 EXPRESSION AND EXPORT OF ANTI-OBESITY PROTEINS AS Fc FUSION PROTEINS
10/10/2001EP1141003A1 Methods
10/10/2001EP1140989A1 Alpha(v) beta(6) integrin inhibitors
10/10/2001EP1140981A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
10/10/2001EP1140970A1 47 human secreted proteins
10/10/2001EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140966A1 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
10/10/2001EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140959A1 Inositol-containing hexasaccharides, their synthesis and their uses
10/10/2001EP1140945A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
10/10/2001EP1140943A2 Substituted pyrroloindoles
10/10/2001EP1140940A1 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)qinoxalin-5(6h)one derivates being 5ht2c agonists
10/10/2001EP1140939A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods
10/10/2001EP1140936A1 Tricyclic inhibitors of poly(adp-ribose) polymerases
10/10/2001EP1140934A1 BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS
10/10/2001EP1140933A2 Process for preparing n6-substituted deaza-adenosine derivatives
10/10/2001EP1140931A1 5ht1 antagonists for antidepressant therapy
10/10/2001EP1140930A1 DIBENZO a,g]QUINOLIZINIUM DERIVATIVES AND THE SALTS THEREOF
10/10/2001EP1140924A1 Piperazine derivatives
10/10/2001EP1140917A1 S-oxide lipid lowering compounds
10/10/2001EP1140916A1 Heteroaryl-cyclic acetals
10/10/2001EP1140914A1 Non-peptide nk1 receptors antagonists
10/10/2001EP1140912A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
10/10/2001EP1140911A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
10/10/2001EP1140908A1 Triazole compounds with dopamine-d3-receptor affinity
10/10/2001EP1140907A1 Triazole compounds with dopamine-d3-receptor affinity
10/10/2001EP1140906A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
10/10/2001EP1140900A2 Pyrazole compounds and uses thereof
10/10/2001EP1140893A1 Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process
10/10/2001EP1140889A2 Compounds and methods for modulation of estrogen receptors
10/10/2001EP1140882A1 Piperazine ethylamide derivatives with 5-ht1a receptor activity
10/10/2001EP1140880A1 Homopiperazine derivatives as selective emopamil inhibitors
10/10/2001EP1140877A1 Hypolipidemic and antioxidant morpholine derivatives
10/10/2001EP1140876A1 Morpholinone and morpholine derivatives and uses thereof
10/10/2001EP1140861A1 Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same
10/10/2001EP1140852A1 1,2,3,4-tetrahydronaphthalenes and their pharamaceutical use
10/10/2001EP1140849A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
10/10/2001EP1140838A1 1, 4-piperazine derivatives having 5ht1a receptor activity
10/10/2001EP1140831A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
10/10/2001EP1140830A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
10/10/2001EP1140823A1 Glucagon antagonists/inverse agonists
10/10/2001EP1140803A1 ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy
10/10/2001EP1140792A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
1 ... 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 ... 1298